MedPath

Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

First Posted Date
2012-07-26
Last Posted Date
2024-10-09
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
1030
Registration Number
NCT01650701
Locations
🇪🇸

Hospital Universitario Vall d´Hebron, Barcelona, Spain

🇪🇸

Hospital Clínico Universitario de Valencia, Valencia, Spain

🇪🇸

Hospital Ramon y Cajal, Madrid, Spain

and more 32 locations

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Not Applicable
Terminated
Conditions
Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage 0 Chronic Lymphocytic Leukemia
Interventions
Drug: lenalidomide
Other: laboratory biomarker analysis
Procedure: lymph node biopsy
Procedure: bone marrow aspiration
Other: pharmacological study
Other: flow cytometry
First Posted Date
2012-07-25
Last Posted Date
2016-06-30
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
8
Registration Number
NCT01649791
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase 2
Withdrawn
Conditions
Multiple Myeloma
First Posted Date
2012-07-20
Last Posted Date
2019-12-12
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT01647165

Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone
First Posted Date
2012-07-20
Last Posted Date
2018-11-08
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
43
Registration Number
NCT01645930

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

Phase 1
Completed
Conditions
Recurrent Follicular Lymphoma
Interventions
Drug: idelalisib
Drug: lenalidomide
First Posted Date
2012-07-19
Last Posted Date
2018-01-30
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
8
Registration Number
NCT01644799
Locations
🇺🇸

MedStar Georgetown University Hospital, Washington, District of Columbia, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 3 locations

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Neutropenia
Acute Myeloid Leukemia (AML)
Myeldysplastic Syndrome (MDS)
Chronic Myelomonocytic Leukemia
Bone Marrow Diseases
First Posted Date
2012-06-27
Last Posted Date
2019-12-17
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
4
Registration Number
NCT01629082
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

NK Cells in Cord Blood Transplantation

Phase 1
Conditions
Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Recurrent Non-Hodgkin Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
DS Stage III Plasma Cell Myeloma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
ISS Stage III Plasma Cell Myeloma
Acute Biphenotypic Leukemia
Recurrent Acute Myeloid Leukemia
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Natural Killer Cell Therapy
Biological: Rituximab
Drug: Tacrolimus
Procedure: Umbilical Cord Blood Transplantation
Radiation: Total-Body Irradiation
First Posted Date
2012-06-14
Last Posted Date
2020-02-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
13
Registration Number
NCT01619761
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Melphalan
Drug: Lenalidomide
First Posted Date
2012-06-12
Last Posted Date
2013-06-21
Lead Sponsor
University of Virginia
Target Recruit Count
1
Registration Number
NCT01617213
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Phase I Study of Lenalidomide in Patients With Acute Leukemia

Phase 1
Terminated
Conditions
Acute Leukemia
Interventions
Drug: Lenalidomide
First Posted Date
2012-06-08
Last Posted Date
2020-05-28
Lead Sponsor
Mehrdad Abedi, MD
Target Recruit Count
6
Registration Number
NCT01615042
Locations
🇺🇸

University of California Comprehensive Cancer Center, Sacramento, California, United States

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Lenalidomide
Drug: Dexamethasone
First Posted Date
2012-06-08
Last Posted Date
2024-10-10
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
45
Registration Number
NCT01615029
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy